Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
06/2000
06/02/2000WO2000031053A1 Il-5 inhibiting 6-azauracil derivatives
06/02/2000WO2000031051A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors
06/02/2000WO2000031050A1 Quinoline and quinoxaline compounds
06/02/2000WO2000031049A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
06/02/2000WO2000031048A1 N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
06/02/2000WO2000031046A1 Novel acylguanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them
06/02/2000WO2000031044A1 Iminoguanidine derivatives, preparation method, use as medicines
06/02/2000WO2000031038A1 Quinoline derivatives as nk-2 and nk-3 receptor ligands
06/02/2000WO2000031037A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
06/02/2000WO2000030715A1 Composition containing an analgesic and a xanthine or a xanthine derivative
06/02/2000WO2000030681A1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
06/02/2000WO2000030677A1 Method of treating viral hemorrhagic fever
06/02/2000WO2000030671A2 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
06/02/2000WO2000030615A1 Method of preparing stable suspensions of insoluble microparticles
06/02/2000WO2000030614A1 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state
06/02/2000WO2000030613A1 New process
06/02/2000WO2000018388A3 Antibiotic compositions for treatment of the eye, ear and nose
06/02/2000WO2000010999A3 New compounds
06/02/2000WO2000008177A3 Death associated kinase containing ankyrin repeats (dakar)
06/02/2000CA2352963A1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases
06/02/2000CA2352599A1 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
06/02/2000CA2352584A1 Quinoline and quinoxaline compounds
06/02/2000CA2352583A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors
06/02/2000CA2352477A1 Compositions comprising angiostatin and kringle 5 region of plasminogen and methods of use thereof
06/02/2000CA2352261A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors
06/02/2000CA2351872A1 Use of activated trap for screening for specific inhibitor of trap and method for aiding in the identification of a compound for use in the treatment of diseases or degenerative conditions resulting in increased bone resorption
06/02/2000CA2351865A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
06/02/2000CA2351725A1 Substituted pyrazoles as p38 kinase inhibitors
06/02/2000CA2351679A1 Prostaglandin conjugates for treating or preventing bone disease
06/02/2000CA2351630A1 Vector
06/02/2000CA2351470A1 Method of treating viral hemorrhagic fever
06/02/2000CA2351361A1 Gtpase associated proteins
06/02/2000CA2351354A1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis
06/02/2000CA2350969A1 Compounds having cytokine inhibitory activity
06/02/2000CA2350759A1 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation
06/02/2000CA2350758A1 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
06/02/2000CA2350755A1 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
06/02/2000CA2350753A1 Benzylmaltosides as inhibitors of smooth muscle cell proliferation
06/02/2000CA2349721A1 N-¬4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl|-acrylamide, an irreversible inhibitor of tyrosine kinases
06/02/2000CA2347940A1 Use of core 2 glcnac transferase inhibitors in treating inflammation
05/2000
05/31/2000EP1004584A2 Pyranoquinoline derivatives as inhibitors of cell proliferation
05/31/2000EP1004578A2 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
05/31/2000EP1003857A2 Secreted proteins and polynucleotides encoding them
05/31/2000EP1003780A1 Human f11 antigen: a cell surface receptor involved in platelet aggregation
05/31/2000EP1003770A1 Secreted proteins and polynucleotides encoding them
05/31/2000EP1003767A1 Human tumor necrosis factor receptor tr10
05/31/2000EP1003763A1 83 human secreted proteins
05/31/2000EP1003751A1 Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
05/31/2000EP1003723A1 2-acylaminopropanamines as tachykinin receptor antagonists
05/31/2000EP1003721A1 Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases
05/31/2000EP1003544A1 C1q AND COLLECTIN RECEPTOR
05/31/2000EP1003514A1 Cyclic amine modulators of chemokine receptor activity
05/31/2000EP1003505A1 Heterocyclic vinylethers against neurological disorders
05/31/2000EP1003504A2 Indole derivatives and their use as mcp-1 antagonists
05/31/2000EP1003499A1 Diclofenac solution for topical application
05/31/2000EP1003492A2 Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins
05/31/2000EP1003486A2 Pharmaceutical compositions containing an effervescent acid-base couple
05/31/2000EP1003479A1 Method and compositions for treating late phase allergic reactions and inflammatory diseases
05/31/2000EP0882016B1 Alkylated styrenes as prodrugs to cox-2 inhibitors
05/31/2000EP0794942B1 Substituted biphenyl compounds for the treatment of inflammation
05/31/2000EP0633775B1 Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor
05/31/2000DE19955340A1 CCR-3-Rezeptor-Antagonisten CCR-3 receptor antagonists
05/31/2000DE19856475A1 Nichtsteroidale Entzündungshemmer Nonsteroidal anti-inflammatory drugs
05/31/2000DE19854749A1 Verwendung von Kapseln, die eine oder mehrere antigene Substanzen enthalten, zur Prävention und/oder Behandlung von Autoimmunerkrankungen The use of capsules which contain one or more antigenic substances, for the prevention and / or treatment of autoimmune diseases
05/31/2000CN1255162A Protease inhibitors
05/31/2000CN1255119A Protease inhibitors
05/31/2000CN1255065A Medicinal preparation containing lipophilicity inert gas
05/31/2000CN1255059A COX-2 selective carprofen for treating pain and inflammation in dogs
05/31/2000CN1254590A Medicinal liquor
05/31/2000CN1254574A Inflammation-relieving antipyretic syrup
05/31/2000CN1254560A Prednelan composition for treating rheumatism
05/31/2000CN1052900C Antisepsis, anti-inflammation and hemostasis capsules
05/31/2000CN1052899C Medicinal liquor for dredging channel and alleviating pain and its making method
05/30/2000US6069162 Indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production
05/30/2000US6069158 10,11-dihydro-3(3-(4-amino-2-pyridylamino)-1-propyloxy)-5h-dib enzo(a,d)cycloheptene-10-acetic acid
05/30/2000US6069135 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents
05/30/2000US6068983 Introducing into cells a dna molecule coding for an fc receptor which is then expressed for increased phagocytic activity; combating infection and/or modulating immune complex disease
05/30/2000US6068851 Formulation for use in the prevention of pathogen induced diseases including HIV and HSV
05/30/2000US6068840 Recombinant CDR-grafted and chimeric anti-IL-8 antibodies containing CDRs or the variable region from the mouse monoclonal antibody, WS-4
05/30/2000CA2119128C Alleviation of symptoms associated with inflammatory disease states
05/30/2000CA2002472C Liquid oral formulation
05/25/2000WO2000029623A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
05/25/2000WO2000029584A1 Antibody variants with higher binding affinity compared to parent antibodies
05/25/2000WO2000029583A2 Immunoglobulin superfamily proteins
05/25/2000WO2000029574A2 Inflammation-associated genes
05/25/2000WO2000029447A1 Rhamm antagonist antibodies
05/25/2000WO2000029445A1 Humanized antibody specific for human 4-1bb and pharmaceutical composition comprising same
05/25/2000WO2000029435A1 12 human secreted proteins
05/25/2000WO2000029422A1 31 human secreted proteins
05/25/2000WO2000029401A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
05/25/2000WO2000029384A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
05/25/2000WO2000029381A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors
05/25/2000WO2000029377A1 4-aroyl-piperidin-ccr-3 receptor antagonists iii
05/25/2000WO2000029023A1 Cox-2 inhibitors in combination with nmda-blockers for treating pain
05/25/2000WO2000028988A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
05/25/2000WO2000028983A1 Novel 4-dedimethy laminotetra cycline derivatives
05/25/2000WO2000028980A2 Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
05/25/2000WO2000028975A2 Improved chemical process and pharmaceutical formulation
05/25/2000WO2000019988A8 NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
05/25/2000WO2000012111A3 Selective treatment of endothelial somatostatin receptors
1 ... 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 ... 1272